DexCom, Inc. (DXCM) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 is constructive but not euphoric — consensus sits at a manageable bar on revenue (~$1.29B, +11% YoY) while the EPS bar ($0.61) is achievable given Q1's strong cost discipline; the single biggest swing factor is whether new patient start momentum sustained its Q1 global-record pace into Q2, which would validate the high end of full-year guidance.

Heading into Q2 2026 results, Dexcom's setup is modestly favorable: the company beat on both revenue and EPS in Q1, raised operating and EBITDA margin guidance, and announced the Prime Therapeutics coverage win (effective summer 2026, adding ~1 million type 2 non-insulin lives), none of which was fully embedded in original guidance. The bar on revenue is not demanding — consensus at ~$1.29B implies ~11% YoY growth, squarely within the reiterated full-year guidance range of $5.16–$5.25B (11–13% growth), and management's Q1 commentary flagged that U.S. comps are harder in H1 and easier in H2, setting a reasonable sequential expectation. Management's tone has been increasingly confident: the May 14 Investor Day formalized a 10%+ organic growth target every year through 2030, authorized a $1B buyback (to be fully executed in 2026), and guided to 29–30% non-GAAP operating margins by 2030 — a posture that signals conviction in the multi-year trajectory. Estimate revisions have been essentially flat since Q1 earnings (Q2 EPS consensus ~$0.589 vs. ~$0.587 at Q1 print), suggesting the Street has not yet priced in upside from the Prime Therapeutics win or the ADA CONNECT trial readout (June 6), leaving modest cushion if execution holds. The stock has rallied ~26% from the April 30 earnings close (~$59.55) to ~$74.85 as of July 28, outperforming XLV meaningfully, so some beat is priced in — but the multiple (NTM P/E ~26x) is not stretched relative to the growth profile. The key wildcard is the pace of G7 15-day conversion and its gross margin pull-through: management guided to ~50% of the U.S. base converting by year-end, and any acceleration or deceleration in that trajectory — combined with geopolitical commodity cost uncertainty (50–100 bps flagged on fuel/resins) — will determine whether gross margin guidance (63–64%) is reiterated, raised, or quietly pressured.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a manageable revenue bar (~$1.29B, +11% YoY) with the EPS bar ($0.61) achievable given Q1's demonstrated cost discipline; new patient starts are the bigger swing factor — Q1 set a global record and the high end of full-year guidance requires records each quarter, making Q2 patient momentum the most watched KPI.

Table 1 — Q2 2026 Current Quarter Snapshot

Source: Visible Alpha consensus and actuals data. Q2 2026 consensus as of July 29, 2026. FY2026 guidance as stated on Q1 2026 earnings call (April 30, 2026). Note: Net New Patients consensus of 148.2K is below Q1's global record of 182.6K, reflecting typical seasonal step-down; the key question is whether Q2 tracks closer to Q1's record pace or reverts toward the low end of guidance.

Table 2 — Beat / Miss History (Last 8 Quarters, Top 2 KPIs)

KPI 1: Total Revenue

KPI 2: Operating EPS (Non-GAAP)

Source: Visible Alpha consensus and actuals data. Pattern: Dexcom has beaten revenue consensus in 7 of the last 7 reported quarters, with beats typically in the +1–3% range — a consistent but modest outperformance pattern. On EPS, the track record is more volatile: two misses in Q4 2024 and Q1 2025 (driven by elevated scrap/freight costs and G7 quality issues) were followed by a sharp recovery, culminating in a +19% EPS beat in Q1 2026 as cost discipline reasserted itself. The Street appears to have learned from the Q1 2026 beat and has modestly raised the Q2 EPS bar, but it remains below the Q1 actual, leaving room for another positive surprise if gross margin holds.

3. Guidance & Commentary Evolution

Key Takeaway: FY2026 revenue and gross margin guidance were reiterated at Q1 earnings (April 30), while operating and EBITDA margin guidance were raised; the May 14 Investor Day added a long-range framework (10%+ organic growth through 2030, $1B buyback) but did not change near-term quarterly guidance. Tone has shifted meaningfully more confident since the Q3 2025 quality-issue trough.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY2026 have been remarkably stable since Q1 earnings — revenue consensus is essentially flat and EPS has barely moved — suggesting the Street has not yet incorporated the Prime Therapeutics win or ADA CONNECT trial data into numbers. This stability represents cushion, not complacency: if Q2 execution matches Q1's pattern, there is room for another modest beat without the bar having been raised.

Source: Visible Alpha consensus and actuals data. Post-Q1 baseline uses consensus as of May 7, 2026 (approximately 5 trading days after the April 30 earnings release). The near-zero revision across all KPIs since Q1 earnings is notable: it suggests the Street is treating Q1 as a clean beat but not extrapolating it forward, leaving the estimate bar essentially unchanged. The FY2026 EPS consensus of $2.597 sits modestly above the May 7 baseline (+0.8%), reflecting the raised operating margin guidance, but has not moved further since — consistent with management's decision to hold revenue guidance flat.

5. Stock Performance

Key Takeaway: The stock's +26% rally since Q1 earnings (April 30 close: $59.55 → July 28 close: $74.85) has been driven primarily by multiple re-rating (+14% NTM EV/EBITDA expansion over 3 months) rather than estimate revisions, which have been flat; the stock has meaningfully outperformed XLV (+14.6% over the same period) and the S&P 500 (+3.1%), suggesting sentiment recovery and Investor Day catalysts are already partially priced in.

Since the Q1 2026 earnings close on April 30, 2026, DXCM has rallied approximately +26% (from $59.55 to $74.85 as of July 28), significantly outperforming the healthcare sector ETF (XLV: +14.6%) and the S&P 500 (+3.1%). The rally was not driven by estimate revisions — consensus revenue and EPS have barely moved — but rather by multiple expansion and sentiment recovery. Key inflection points include: (1) the May 14 Investor Day, which catalyzed a sharp move from ~$58 to ~$72 over the following week as the long-range plan and $1B buyback were well-received; (2) the June 6–8 ADA conference period, where the CONNECT trial readout and positive peer commentary (Insulet, Abbott) drove DXCM to a near-term high of ~$78; and (3) a mid-June to late-June pullback to ~$67–69 as the broader market softened and the stock digested gains. The stock recovered to ~$78 on July 16 (Abbott Q2 earnings day, positive CGM read-through) before settling back to ~$74–75 heading into the print. At current levels, NTM P/E of ~26x and EV/EBITDA of ~15.7x are below the 12-month-ago levels (P/E ~38.6x, EV/EBITDA ~21.7x), reflecting the valuation reset from 2025's guidance cuts, but the 3-month multiple expansion (+14% on EV/EBITDA) signals the market is beginning to re-rate the stock toward its growth profile.

Note: Sector ETF used: XLV (Health Care Select Sector SPDR Fund). XLV is appropriate for DXCM as a large-cap medical device/diabetes technology company within the healthcare sector. Chart below is indexed to 100 at April 30, 2026 (Q1 2026 earnings date). Data through July 28, 2026 (July 29 is the preparation date; July 30 earnings data excluded).

Source: Yahoo Finance / Stock Price Data. Indexed to 100 at April 30, 2026 close. Data through July 28, 2026. July 29 (preparation date) and July 30 (earnings date) excluded per instruction.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the May 14 Investor Day, which formalized a 10%+ organic growth LRP through 2030 and a $1B buyback — a structural re-rating catalyst; the June 6 ADA CONNECT trial readout and Abbott's July 16 CGM commentary are the most relevant near-term read-throughs for Q2 setup.

• May 14, 2026 — Investor Day (Mesa, AZ): Dexcom formalized its long-range plan: 10%+ organic revenue growth every year through 2030 (not a CAGR), non-GAAP operating margin of 29–30% and adjusted EBITDA margin of 36–37% by 2030, and non-GAAP gross margin growing into the high 60s. Board authorized a $1.0B share repurchase program (terminating the prior $250M program), to be fully executed in 2026, with 50%+ of annual FCF committed to buybacks going forward. Management also disclosed CMS coverage expected “anytime between now and end of 2026,” with internal plans assuming coverage effective mid-2027 (adding ~12M lives). Tandem compatibility with G7 15-day announced. Implication: Structural positive; the LRP and buyback commitment were the primary drivers of the post-Q1 re-rating.
• June 6, 2026 — ADA Scientific Sessions: CONNECT Trial Readout: Dexcom presented the full readout of its randomized controlled trial for type 2 non-insulin patients (CONNECT trial) at the American Diabetes Association 2026 Scientific Sessions in New Orleans. Management had flagged this as the “defining study” for the population and a cornerstone for global payer evidence. The readout was anticipated to strengthen the case for CMS coverage. Implication: Positive catalyst for CMS coverage timeline; data quality will determine whether CMS acts in 2026 or early 2027.
• May 14, 2026 — Governance Enhancements: Dexcom announced governance enhancements ahead of Investor Day, including working with Elliott Management to recruit two new Board directors with medtech and high-volume operations experience. The Technology Committee was repurposed into the Operations and Innovation Committee. A new Chief Product Officer role is being recruited. Implication: Signals responsiveness to activist pressure and operational focus; neutral to modestly positive for investor confidence.
• May 2026 — Tandem Compatibility with G7 15-Day: Dexcom announced compatibility of its G7 15-day sensor with Tandem's pump system, joining Beta Bionics and Insulet. This expands the addressable AID market for G7 15-day. Implication: Positive for G7 15-day adoption and new patient starts in the AID segment.
• July 16, 2026 — Abbott (ABT) Q2 2026 Earnings: Abbott reported CGM (FreeStyle Libre) sales exceeding $2B, reflecting 9.5% growth in Q2 2026. Abbott CEO Robert Ford stated the CGM market has 75–80M potential users globally vs. only 15M currently, and that reimbursement expansion (including U.S. Type 2 Medicare, potentially “in the fall”) could be a “multibillion dollar opportunity.” Abbott stock surged 14% on the day. DXCM rose ~7% in sympathy. Implication: Strong positive read-through: validates CGM market growth, reimbursement expansion timeline, and demand durability. Abbott's 9.5% CGM growth provides a market-level benchmark.
• July 9, 2026 — Q2 Earnings Date Confirmed: Dexcom confirmed Q2 2026 earnings release and conference call for July 30, 2026 at 4:30 PM ET. Implication: Procedural; no new information.
• Q2 2026 (ongoing) — Prime Therapeutics Coverage Effective: Prime Therapeutics coverage for Dexcom CGM for all people with diabetes became effective “this summer” (as stated on Q1 call, April 30). This adds approximately 1 million type 2 non-insulin lives, bringing total commercial coverage to more than 7 million lives by year-end. Implication: Positive for Q2 and H2 new patient starts; management noted this was not a major contributor to original guidance, so any pull-through represents upside.
• Q2 2026 (ongoing) — New Patch Technology Market Launch: Dexcom's new adhesive patch technology (FDA clearance received in Q1 2026) was expected to “reach the market in the coming weeks” from the April 30 call, implying a Q2 2026 launch. Designed to improve sensor survivability and wear experience across the product portfolio. Implication: Positive for sensor retention rates and NPS scores; could reduce dropout rates and support new patient start momentum.
• Q2 2026 (ongoing) — Stelo App Redesign: A complete redesign of the Stelo app was expected “in the coming weeks” from the April 30 call, featuring a more consumer-friendly interface, AI-driven personalized insights, and enhanced food/nutrition logging. International Stelo launch planned for 2026 (Korea, Australia, New Zealand, then U.K.). Implication: Positive for Stelo engagement and international expansion; near-term revenue contribution remains de minimis.

7. Insider Transaction Activity

Key Takeaway: All insider transactions since Q1 earnings are 10b5-1 planned sales — there are no discretionary open-market sells or buys. The pattern is routine and pre-scheduled; no clustered discretionary selling or unusual transaction sizes stand out as a negative signal heading into Q2 earnings.

Source: SEC Form 4 filings and Form 144 filings. All transactions are open-market sales executed under pre-established 10b5-1 trading plans. No open-market discretionary buys or sells were filed in the period. The absence of any discretionary buying is not unusual for a company whose stock has rallied ~26% since Q1 earnings. Kevin Sayer's monthly ~26,750-share sales are the largest by volume but are consistent with a long-running pre-scheduled plan. No insider transaction activity raises a flag heading into Q2 earnings.

8. Peer Commentaries & Read-Throughs

Scope: Includes only commentary issued between May 30 and July 29, 2026, where the speaker addressed their then-current unreported quarter or forward second-half outlook. Retrospective prior-quarter commentary is excluded. Disclosure dates are noted separately from effective dates where applicable.

Abbott Laboratories (ABT) — Q2 2026 Earnings Call

Disclosure Date: July 16, 2026 | Period Addressed: Q2 2026 (then-current reported quarter) and H2 2026 forward outlook

• CGM Market Size & Growth Rate: Abbott CEO Robert Ford stated there are “75 to 80 million people around the world that could realistically be on a CGM” but only “15 million so far,” indicating “plenty of opportunity for growth and growth acceleration.” Abbott's CGM (FreeStyle Libre) sales exceeded $2 billion in Q2 2026, reflecting 9.5% growth — slightly below the double-digit expectations management had set, but described as calming investor nerves about deceleration. DXCM Read-Through: Positive. The 9.5% CGM growth rate provides a market-level benchmark; if the overall market is growing at high single digits without major reimbursement unlocks, Dexcom's 11%+ consensus implies modest share gain or mix benefit from G7 15-day. The large untapped market (75–80M potential users) validates the long-term growth runway.
• U.S. Type 2 Medicare Reimbursement Timing: Ford stated the U.S. Type 2 Medicare coverage decision “could happen in the fall” and would unlock “around 10 million Medicare beneficiaries” and “accelerate commercial insurance coverage,” calling it a “multibillion dollar opportunity.” He noted he “can’t forecast exactly when” but expressed confidence it will “definitely accelerate” sales when it occurs. DXCM Read-Through: Highly positive. Abbott's CEO — a direct competitor — independently corroborating a “fall 2026” CMS coverage timeline aligns with Dexcom's own Investor Day guidance (“anytime between now and end of 2026”). This is the most important near-term catalyst for DXCM and is not yet in consensus numbers.
• Market Growth Without Reimbursement Expansion: Ford noted that without a major reimbursement expansion, the CGM market grows at “eight, 9%” — “not a bad growth rate” but below historical peaks. He emphasized that reimbursement expansions “drastically accelerate” the growth rate, as seen in France, Japan, and Canada. DXCM Read-Through: Contextually important: Dexcom's 11–13% FY2026 guidance implies modest outperformance vs. the market baseline, achievable through G7 15-day mix shift and new patient starts. The “drastically accelerate” comment reinforces the CMS coverage optionality.
• Libre Duo CE Mark & U.S. FDA Discussions: Abbott secured CE mark for Libre Duo (world’s first dual glucose-ketone wearable sensor) in May 2026, with international rollout planned for fall 2026 and U.S. FDA discussions in “very, very advanced kind of final stages.” Abbott also disclosed two additional undisclosed CGM pipeline programs. DXCM Read-Through: Mildly negative competitive signal. Libre Duo’s international rollout in fall 2026 introduces a differentiated product into markets where Dexcom competes. However, Dexcom’s G8 (expected submission 2027, launch late 2027/early 2028) is also targeting a smaller form factor and advanced sensing, so the competitive response is in the pipeline.
• Manufacturing Capacity Expansion: Abbott is in “final stages of planning for a fifth manufacturing facility” — a $1B investment for a 100-million-sensor facility — due to expected capacity constraints at its fourth facility “in the next couple of years.” DXCM Read-Through: Positive for the market. Abbott’s $1B capacity investment signals confidence in sustained high-volume CGM demand, validating the long-term market growth thesis that underpins Dexcom’s own Ireland facility ramp.

Insulet Corporation (PODD) — William Blair Growth Stock Conference

Disclosure Date: June 3, 2026 | Period Addressed: Q2 2026 (then-current unreported quarter) and H2 2026 forward outlook

• Full-Year 2026 Revenue Guidance Raised: Insulet raised its FY2026 revenue guidance to 21–23% growth (from prior 20–22%) following strong Q1 customer base growth, and stated it expects “higher new starts in 2026 than in 2025.” The company reiterated “high confidence” in its 20% CAGR LRP for 2026–2028. DXCM Read-Through: Positive. Insulet’s raised guidance and higher new-start expectations for 2026 signal strong AID system adoption, which directly drives CGM demand. As a leading CGM provider integrated with Omnipod, Dexcom benefits from Insulet’s growth.
• Omnipod 5 Now Compatible with FreeStyle Libre 3 Plus: Announced June 3, 2026: Omnipod 5 is now compatible with Abbott’s FreeStyle Libre 3 Plus, making it easier for approximately 450,000 MDI users already wearing Libre 3 Plus to start on Omnipod 5. International Libre Plus compatibility planned for Germany and Canada in H2 2026. DXCM Read-Through: Negative. This is the most direct competitive negative in the peer commentary: Insulet is explicitly enabling AID adoption for Libre users, potentially diverting new AID starts away from Dexcom-integrated pathways. The 450,000 MDI users already on Libre 3 Plus represent a pool that previously would have needed to switch to Dexcom to access Omnipod 5.
• Sales Force Expansion (H2 2026): Insulet is expanding its sales force by more than 10% in H2 2026 to call on “several thousand additional prescribers who care for about 150,000 more people with diabetes.” DXCM Read-Through: Positive. Broader prescriber engagement for AID systems expands the overall diabetes technology market, including CGM. More prescribers writing AID scripts means more CGM prescriptions.
• Market Underpenetration: Insulet highlighted that the U.S. Type 1 market is only 40–45% penetrated, the global Type 1 market only 25% penetrated, and the U.S. Type 2 basal bolus market only ~5% penetrated (a $12B TAM). DXCM Read-Through: Positive. Low penetration rates across all diabetes segments validate the long-term growth runway for CGM. Insulet’s 2028 “disruptive offering” for the Type 2 basal bolus market (designed to be “as simple to prescribe as CGM”) would, if successful, dramatically expand CGM demand.

Insulet Corporation (PODD) — ADA Cardiometabolic Health Portfolio Investor Event

Disclosure Date: June 8, 2026 | Period Addressed: Q2 2026 (then-current unreported quarter) and H2 2026 / 2027 forward outlook

• GLP-1 and Insulin Use: Complementary, Not Competitive: Insulet presented data from the Epic Cosmos database showing that 41% of Type 2 patients are estimated to be on GLP-1s in 2025, yet insulin use has remained constant at 26% since 2007. Studies also showed that CGM use combined with GLP-1s resulted in faster and greater weight loss than either alone. DXCM Read-Through: Positive. This directly addresses the GLP-1 displacement risk for CGM. The data confirms that GLP-1 growth is not cannibalizing the insulin-using Type 2 market, and the complementary CGM+GLP-1 weight loss data opens a potential new indication for CGM beyond traditional insulin users.
• Omnipod 6 STRIVE Study Results: Insulet presented STRIVE pivotal study results for Omnipod 6 (launch planned 2027): 4% uplift in time-in-range (73% to 77% for Type 1 adults), 7% increase in time-in-tight-range, and a 40% reduction in boluses while maintaining similar glycemic outcomes. Omnipod 6 will feature improved Pod-CGM connectivity and over-the-air pod updates. DXCM Read-Through: Positive. Improved AID performance drives overall pump adoption, benefiting CGM. Over-the-air pod updates could reduce friction for CGM model upgrades (e.g., G7 to G8), facilitating Dexcom’s own product transitions.
• Fully Closed-Loop for Type 2 (Evolve Trial): Insulet commenced enrollment for the Evolve pivotal trial for a fully closed-loop system for Type 2 diabetes (~300 patients), targeting submission in 2027 and launch in 2028. The system is designed to be “100% hands off” with no settings entry and no bolusing required. Target market: 2.5–5.5M insulin-using Type 2 patients in the U.S. with almost no pump use today. DXCM Read-Through: Highly positive. A hands-off AID system for Type 2 patients — the largest untapped market for diabetes technology — would dramatically expand CGM demand if adopted at scale. Insulet explicitly envisions patients connecting to CGM as part of this system.

Tandem Diabetes Care (TNDM) — Goldman Sachs Global Healthcare Conference

Disclosure Date: June 8, 2026 | Period Addressed: Q2 2026 (then-current unreported quarter) and H2 2026 forward outlook

• GLP-1 Risk Resolved: Tandem CEO John Sheridan stated the company has “gotten past that hurdle” regarding GLP-1 impact on Type 2 patients, citing clinical studies showing GLP-1s and Control-IQ are “a complementary situation where you need both.” He concluded it is “no longer the risk that people had perceived.” DXCM Read-Through: Positive. A second major AID company independently confirming GLP-1 complementarity reinforces the market-level thesis that CGM demand is not at risk from GLP-1 adoption.
• Market Growth Outlook for 2026: Sheridan stated he anticipates “continued growth in ’26 and beyond,” driven by new technology reducing patient burden and improving performance. He acknowledged Q1 seasonality and macro factors (inflation, cost of gas) making patients “more cautious when it comes to spending,” but dismissed concerns about a structural market slowdown. DXCM Read-Through: Positive. Tandem’s optimistic 2026 growth outlook for the pump market supports Dexcom’s own new patient start guidance. The macro caution note is worth monitoring for Q2 patient start data.
• Mobi Tubeless Filing & H2 Launch: Tandem stated it will “file in the second quarter” for Mobi tubeless and expects to “commercialize” it in H2 2026, targeting the tubeless market growing “in excess of 20%.” Tandem expects “double-digit growth,” “significant growth in MDI starts,” and “competitive conversions go up” with the tubeless launch. DXCM Read-Through: Positive. Tandem’s tubeless entry into a 20%+ growth market expands the overall AID addressable market, driving CGM demand. Tandem’s primary CGM partner has historically been Dexcom.
• Pharmacy Channel Transition: Tandem’s pharmacy channel transition (launched March 2026) is progressing, with 40% formulary coverage achieved by Q1 exit (vs. 40–50% full-year target). CFO Leigh Vosseller expects 80% of pumps to go through pharmacy in 2–3 years, dramatically reducing out-of-pocket costs (the “$1,000 DME” barrier). DXCM Read-Through: Positive. Lower out-of-pocket costs for pumps reduce the total cost of diabetes technology adoption, which benefits CGM as an integrated component. The pharmacy channel shift is a structural tailwind for the entire diabetes tech ecosystem.

Senseonics (SENS) — Analyst Event

Disclosure Date: June 6, 2026 | Period Addressed: Q2 2026 (then-current unreported quarter) and H2 2026 / 2027 forward outlook

• CGM Market Growth Rate Moderating: Senseonics CEO Tim Goodnow noted the CGM market CAGR has moderated from “well over 25%” to “around 20% or high teens,” attributed to increased penetration by “some of the larger guys.” The overall market is “over a $13 billion market.” DXCM Read-Through: Mildly negative context. A moderating market CAGR is consistent with Abbott’s 9.5% CGM growth and the broader thesis that the market needs reimbursement unlocks to re-accelerate. Dexcom’s 11–13% guidance implies outperformance vs. the market baseline.
• Transcutaneous CGM Commoditization: Goodnow characterized the transcutaneous CGM market (Dexcom and Abbott) as having “coalesced to the same product,” with both now at 15-day wear and similar glucose oxidase technology. He noted the winner in transcutaneous will be determined by “best high-volume manufacturing.” He also referenced Dexcom’s G8 announcement, noting it will “approach the Libre size in regards to the transmitter.” DXCM Read-Through: Neutral to mildly negative. The commoditization narrative is a competitive framing from a smaller rival, but it highlights the importance of Dexcom’s manufacturing efficiency (Ireland ramp, scrap reduction) and G8 differentiation as the next product cycle.
• Reliability/Accuracy Issues Referenced: TD Cowen analyst Joshua Jennings noted that Senseonics’ positive data comes “in a time where there’s been some reliability and accuracy issues within the field with some of the other CGM players.” Stifel analyst Jonathan Block echoed that Eversense awareness is rising “both as a combination of direct-to-consumer marketing and also some of the struggles that other sensors are going through.” DXCM Read-Through: Mildly negative. These analyst comments reference the G7 quality/complaint issues from 2025. Management stated on the Q1 2026 call that complaint rates have stabilized and G7 15-day NPS scores have “jumped up,” but the perception risk lingers in the competitive narrative.
• Senseonics Revenue Guidance Raised: Senseonics raised its 2026 revenue guidance to $60–64M (80%+ YoY growth) and raised gross margin guidance to 55–58%. The company raised over $100M in growth capital to fund through the Freedom product launch. DXCM Read-Through: Neutral. Senseonics remains a very small competitor ($60–64M revenue vs. Dexcom’s $5.2B). Its growth is from a tiny base and does not represent a material near-term competitive threat to Dexcom’s market position.

Medtronic (MDT) — Q4 FY2026 Earnings Release

Disclosure Date: June 3, 2026 | Period Addressed: FY2027 forward outlook (Medtronic’s FY2027 begins April 25, 2026, covering the period that overlaps with Dexcom’s Q2–Q4 2026)

• FY2027 Organic Revenue Growth Guidance Includes Diabetes: Medtronic guided to FY2027 organic revenue growth of 6.75–7.25%, explicitly including “revenue from the Diabetes business for the full fiscal year.” FY2027 diluted non-GAAP EPS guidance of $5.90–$6.00 (6.7–8.5% growth) “assumes consolidation of the Diabetes business for the full 12 months of FY2027.” DXCM Read-Through: Positive. Medtronic’s continued inclusion of its Diabetes (MiniMed) business in FY2027 guidance signals a stable and growing diabetes technology market. The full-year consolidation assumption implies no near-term disruption to the competitive landscape from the pending separation.
• Diabetes Business Separation Pending: Medtronic stated the separation of its Diabetes business is expected through “a series of capital markets transactions” (spin-off, split-off, offering, or combination). The “current preferred structure” is “an offering and split-off,” but “a final decision has not been reached.” Separation-related charges are already being incurred. DXCM Read-Through: Mixed. A standalone MiniMed could become a more focused and agile competitor with its own capital structure and strategic flexibility. However, the separation process creates near-term organizational distraction for Medtronic’s diabetes team, which may benefit Dexcom in the interim. The uncertainty around the final structure means the competitive implications are still evolving.

Peer Commentary Summary Table

Overall Peer Read-Through Assessment: The peer commentary since May 30 is net positive for Dexcom heading into Q2 earnings. The most important signal is Abbott’s independent corroboration of a “fall 2026” CMS coverage timeline — a catalyst not in consensus numbers. GLP-1 complementarity is now confirmed by two AID companies (Insulet and Tandem), removing a key bear thesis. The one notable negative is Insulet’s Libre 3 Plus compatibility announcement (June 3), which creates a new pathway for AID adoption that bypasses Dexcom CGM — a competitive dynamic to monitor in new patient start data. The CGM market growth rate of 8–10% without reimbursement unlocks (per Abbott) sets a reasonable baseline against which Dexcom’s 11–13% guidance implies modest outperformance.